[Lutetium-177]Lu-PSMA-617 Delays Quality-of-Life Decline, Pain Progression, and Symptomatic Skeletal Events in PSMA-Positive mCRPC: In-depth PSMAfore Analysis

Highlights

– In the phase 3 PSMAfore trial, [177Lu]Lu-PSMA-617 delayed deterioration in patient-reported health-related quality of life (FACT-P and EQ-5D-5L) and pain (BPI-SF) versus a change in androgen receptor pathway inhibitor (ARPI) in taxane‑naive, PSMA PET–positive metastatic castration‑resistant prostate cancer (mCRPC).

– Median time to FACT-P deterioration was 7.46 months with [177Lu]Lu-PSMA-617 versus 4.27 months with ARPI change (HR 0.61, 95% CI 0.50–0.75).

– [177Lu]Lu-PSMA-617 substantially reduced risk of first symptomatic skeletal event (SSE) (HR 0.41, 95% CI 0.26–0.63); median time to first SSE was not reached with radioligand therapy versus 17.97 months with ARPI change.

Background and clinical context

Metastatic castration‑resistant prostate cancer (mCRPC) remains a major cause of morbidity and mortality in men with advanced prostate cancer. Pain, functional decline, and skeletal complications drive much of the quality‑of‑life burden in this population. For men whose disease progresses on an androgen receptor pathway inhibitor (ARPI), sequencing options historically have included chemotherapy (docetaxel, cabazitaxel), alternative ARPIs in selected settings, bone‑targeted agents, and best supportive care. The approval of lutetium‑177–labelled PSMA‑617 (vipivotide tetraxetan, commercial name pluvicto) introduced a targeted radioligand therapy for PSMA‑positive mCRPC, with prior pivotal data (VISION, TheraP) demonstrating antitumor activity and overall survival benefit in later lines of therapy.

Study design and patient population

PSMAfore is an international, open‑label, randomised phase 3 trial (NCT04689828) that compared [177Lu]Lu‑PSMA‑617 versus change of ARPI (abiraterone or enzalutamide per local labelling) in taxane‑naive patients with PSMA PET–positive mCRPC who had progressed once on a prior ARPI. Key eligibility included age ≥18 years, ECOG performance status 0–1, and confirmation of at least one PSMA‑positive metastatic lesion without exclusionary PSMA‑negative lesions on 68Ga‑PSMA‑11 PET‑CT. Participants were randomized 1:1 to receive [177Lu]Lu‑PSMA‑617 (7.4 GBq every 6 weeks for up to six cycles) or ARPI change. The primary endpoint of the trial was radiographic progression‑free survival (rPFS); secondary endpoints included time to worsening of health‑related quality of life (HRQOL; FACT‑P, EQ‑5D‑5L), pain (BPI‑SF), and time to first symptomatic skeletal event (SSE). Analyses reported here are from the third interim overall survival analysis (data cutoff Feb 27, 2024) and were conducted on an intention‑to‑treat basis.

Key findings

Population and follow‑up

Between June 15, 2021, and Oct 7, 2022, 468 patients were randomized (234 to [177Lu]Lu‑PSMA‑617; 234 to ARPI change). Median follow‑up to the third interim cutoff was approximately 24.1 months in both groups. The cohort was predominantly White (91%); 3% were Black/African American.

Health‑related quality of life

Across prespecified HRQOL instruments, [177Lu]Lu‑PSMA‑617 delayed time to clinically meaningful worsening versus ARPI change. For FACT‑P total score, median time to worsening was 7.46 months (95% CI 6.08–8.54) with [177Lu]Lu‑PSMA‑617 versus 4.27 months (95% CI 3.45–4.50) with ARPI change (hazard ratio [HR] 0.61, 95% CI 0.50–0.75). For EQ‑5D‑5L utility score, median time to worsening was 6.28 months (95% CI 4.70–7.89) versus 3.88 months (95% CI 3.25–4.44; HR 0.67, 95% CI 0.54–0.82). These findings indicate both a delay in decline and a clinically meaningful preservation of patient‑reported global health and functioning with radioligand therapy.

Pain outcomes

Pain intensity, measured by the Brief Pain Inventory‑Short Form (BPI‑SF), also favored [177Lu]Lu‑PSMA‑617. Median time to worsening in pain intensity was 5.03 months (95% CI 4.40–6.80) with [177Lu]Lu‑PSMA‑617 versus 3.65 months (95% CI 3.09–4.37) with ARPI change (HR 0.72, 95% CI 0.59–0.88). These data suggest that earlier use of PSMA‑targeted radioligand therapy provides symptomatic benefit by delaying escalation or deterioration of cancer‑related pain.

Symptomatic skeletal events

Compellingly, [177Lu]Lu‑PSMA‑617 reduced the risk of first symptomatic skeletal event (SSE) relative to ARPI change. Median time to first SSE was not reached in the [177Lu]Lu‑PSMA‑617 group (95% CI not estimable) compared with 17.97 months (95% CI 14.26–NE) in the ARPI change group (HR 0.41, 95% CI 0.26–0.63). This represents a clinically important reduction in skeletal morbidity—fractures, spinal cord compression, or palliative bone procedures—that directly impair function and quality of life.

Safety

Treatment‑emergent adverse events of grade 3 or higher were similar between arms for the most common event; anaemia occurred in 6% (14/227) of patients receiving [177Lu]Lu‑PSMA‑617 and 7% (16/232) of those on ARPI change. There were no treatment‑related deaths in the [177Lu]Lu‑PSMA‑617 arm and one treatment‑related death (cerebrovascular accident) in the ARPI change arm. The safety profile aligns with prior trials of lutetium‑177 PSMA‑617, where hematologic toxicity and xerostomia are notable adverse effects; long‑term renal and marrow effects remain areas for surveillance.

Expert commentary and interpretation

PSMAfore adds important patient‑centered data to the evolving role of [177Lu]Lu‑PSMA‑617 in mCRPC. Beyond radiographic control, delaying deterioration in HRQOL and pain and reducing SSEs are highly meaningful outcomes for patients and caregivers. The magnitude of effect on SSEs (HR 0.41) is particularly notable because skeletal complications are a major driver of morbidity in prostate cancer and often precipitate loss of independence.

Mechanistically, PSMA‑targeted radioligand therapy delivers focused beta radiation to PSMA‑expressing tumor deposits, achieving cytoreduction that likely translates to sustained symptomatic benefit. PSMA PET selection enriches for target expression and may explain the favorable patient‑reported outcomes observed.

Limitations and generalizability

Important limitations should be considered when applying PSMAfore findings to routine practice. The trial was open‑label, which may influence self‑reported outcomes despite the objectivity of validated instruments. The study population was predominantly White; underrepresentation of racial and ethnic minorities limits assessment of treatment effects across diverse groups. Patients were taxane‑naive and had progressed on a single prior ARPI—thus results apply primarily to this specific sequencing decision and cannot be extrapolated directly to heavily pretreated or post‑taxane populations.

Access to high‑quality 68Ga‑PSMA‑11 PET‑CT is a prerequisite for patient selection; disparities in imaging availability and reimbursement may limit generalizability. Cost, logistics for radiopharmaceutical production and delivery, and local nuclear medicine expertise will influence real‑world implementation. Finally, overall survival follow‑up was ongoing at the time of this analysis; mature OS data are needed to fully define the tradeoff between earlier radioligand therapy and alternative systemic sequencing strategies.

Clinical implications and practice considerations

For clinicians managing taxane‑naive patients with PSMA‑positive mCRPC who have progressed on a prior ARPI, PSMAfore supports consideration of [177Lu]Lu‑PSMA‑617 as a strategy that not only delays radiographic progression but also meaningfully preserves quality of life, reduces pain progression, and decreases skeletal morbidity. Decision‑making should be individualized and factor in PSMA PET results, cardiorespiratory and marrow reserve, access to PSMA radioligand therapy, concurrent bone‑targeted agents (denosumab/zoledronic acid), and patient preferences regarding routes of therapy and expected toxicities.

Multidisciplinary management—including medical oncology, nuclear medicine, radiation oncology, urology, palliative care, and supportive services—optimizes patient selection and management of adverse events. Ongoing surveillance for hematologic toxicity and potential long‑term sequelae is essential.

Conclusion

PSMAfore provides rigorous evidence that [177Lu]Lu‑PSMA‑617, when used in taxane‑naive, PSMA PET‑positive mCRPC after progression on one ARPI, delays deterioration in health‑related quality of life and pain and substantially reduces risk of symptomatic skeletal events compared with switching ARPI. These patient‑centered benefits strengthen the rationale for integrating PSMA‑targeted radioligand therapy into treatment sequencing discussions, while underscoring the need for equitable access to PSMA PET imaging and radiopharmaceutical therapy, longer OS follow‑up, and broader representation in future trials.

Funding and trial registration

The PSMAfore trial was funded by Novartis. ClinicalTrials.gov identifier: NCT04689828.

References

1. Fizazi K, Morris MJ, Shore ND, et al. Health‑related quality of life, pain, and symptomatic skeletal events with [177Lu]Lu‑PSMA‑617 in patients with progressive metastatic castration‑resistant prostate cancer (PSMAfore): an open‑label, randomised, phase 3 trial. Lancet Oncol. 2025;26(7):948‑959. doi:10.1016/S1470‑2045(25)00189‑5.

2. Sartor O, de Bono J, Chi KN, et al. Lutetium‑177‑PSMA‑617 for Metastatic Castration‑Resistant Prostate Cancer. N Engl J Med. 2021;385(12):1091‑1103. doi:10.1056/NEJMoa2107322. (VISION trial)

3. Hofman MS, Emmett L, Sandhu S, et al. [177Lu]Lu‑PSMA‑617 for metastatic castration‑resistant prostate cancer: a randomized phase II trial (TheraP). Lancet. 2021;397(10276):797‑804. doi:10.1016/S0140‑6736(21)00237‑4.

4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 4.2024. Available at: https://www.nccn.org (accessed 2025).